Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19
Status:
Completed
Trial end date:
2020-04-23
Target enrollment:
Participant gender:
Summary
This is a compassionate use, proof of concept, phase IIb, prospective, interventional, pilot
study in which the investigators will evaluate the effects of compassionate-use treatment
with IV tirofiban 25 mcg/kg, associated with acetylsalicylic acid IV, clopidogrel PO and
fondaparinux 2.5 mg s/c, in patients affected by severe respiratory failure in Covid-19
associated pneumonia who underwent treatment with continuous positive airway pressure (CPAP).
Phase:
Phase 2
Details
Lead Sponsor:
University of Milan
Collaborator:
Fondazione "Un Cuore per Milano" - a no profit foundation